CFO Matthew K. Szot Sells Shares in Cadrenal Therapeutics

Matthew K. Szot, the Chief Financial Officer of Cadrenal Therapeutics, Inc., sold 1,800 shares of the company's common stock on October 24, 2025, and another 1,800 shares on October 27, 2025, at a price of $13.99 per share. These sales were conducted in accordance with a Rule 10b5-1 trading arrangement adopted by Szot on May 9, 2025. Following these transactions, Szot's ownership in the company decreased to 11,733 shares after the first sale and further to 9,933 shares after the second sale. The transactions were reported in a Form 4 filing with the SEC.